Novartis appoints Bertrand Bodson as Chief Digital Officer

NovartisNovartis announced today that Bertrand Bodson, Chief Digital and Marketing Officer for Sainsbury's Argos, has been appointed to the new role of Chief Digital Officer, reporting to Joseph Jimenez, CEO of Novartis. He will join Novartis on January 1, 2018, and will be responsible for creating and executing a company-wide digital strategy in close collaboration with the Executive Committee of Novartis, working with leadership teams across the business and external partners. Mr. Bodson will lead the digital transformation Novartis has embarked upon to improve the way the Company uses data in drug discovery and development, engages with patients, doctors and other stakeholders, as well as automating business processes.

"Bertrand has a proven track record of creating and implementing successful digital strategies across global companies, and leading cultural change in order to make this happen at scale," said Mr. Jimenez. "This is not just about digital helping the business. Bertrand will help us transform our business model using digital technologies."

Mr. Bodson has extensive experience as a senior executive and entrepreneur across a variety of industries. In his current role at Sainsbury's Argos, he has led a highly successful transformation from a traditional catalogue business to the third-largest online retailer in the UK.

Mr. Bodson said: "I am very excited to be joining Novartis to play a part in its efforts to reimagine medicine by leveraging digital on behalf of millions of patients and practitioners. While this will be one of the most important and disruptive challenges in the years to come Novartis, as a global leader, is particularly well positioned to drive this, and have even greater and sustainable impact on healthcare worldwide."

He is a Belgian citizen and has lived and worked in Europe and North America. Prior to Sainsbury's Argos he held a senior role at EMI Music and co-founded Bragster.com, a social networking and content sharing website. Mr. Bodson also held senior roles at online retailer Amazon, both in Seattle and across Europe. He started his career in 1998 at Boston Consulting Group.

Mr. Bodson has an MBA from Harvard Business School in the United States and a Masters of Commercial Engineering from the Solvay Business School/McGill University in Belgium and Canada.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...